Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age

To evaluate the impact of the American Academy of Pediatrics revised recommendations (2014) for palivizumab prophylaxis on respiratory syncytial virus (RSV) admissions and severity of illness among children ≥29 weeks and

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 2019-06, Vol.209, p.125-129
Main Authors: Zembles, Tracy N., Bushee, Glenn M., Willoughby, Rodney E.
Format: Article
Language:English
Subjects:
Academies and Institutes
Antiviral Agents - therapeutic use
Female
Gestational Age
guidelines
Humans
Infant
Infant, Newborn
Male
palivizumab
Palivizumab - therapeutic use
Patient Admission - statistics & numerical data
pediatric
Pediatrics
Practice Guidelines as Topic
respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Retrospective Studies
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the impact of the American Academy of Pediatrics revised recommendations (2014) for palivizumab prophylaxis on respiratory syncytial virus (RSV) admissions and severity of illness among children ≥29 weeks and
ISSN:0022-3476
1097-6833
DOI:10.1016/j.jpeds.2019.02.020